mRNA vaccines are showing encouraging results in the treatment of certain types of cancer. In the coming years, such treatments could be reimbursed in Switzerland by health insurance companies, as Solange Peters, head of oncology at Vaud University Hospital (CHUV), assumes.
For the first time, vaccines produced by manufacturers Moderna and Merck based on messenger ribonucleic acid have shown promising success in the treatment of melanoma (black skin cancer), Peters said on radio RTS in western Switzerland.
According to a semi-completed study, the risk of recurrence is significantly reduced after melanoma surgery and treatment with an mRNA vaccine. The US Food and Drug Administration (FDA) has already approved the treatment method early.
In Switzerland, trials are being conducted in five university hospitals with mRNA vaccines against melanoma, says Peters. According to the cancer specialist, it will take a few years before a health insurer is approved in Switzerland and Europe, but not two decades. (aeg/sda)
Source: Blick
I am Ross William, a passionate and experienced news writer with more than four years of experience in the writing industry. I have been working as an author for 24 Instant News Reporters covering the Trending section. With a keen eye for detail, I am able to find stories that capture people’s interest and help them stay informed.
